U.S. — Federal regulators are reviewing whether to allow compounding pharmacies to manufacture seven peptides, including TB-500, BPC-157, and MOTs-C. The Pharmacy Compounding Advisory Committee is scheduled to make recommendations on July 23, 2026.

The committee will review data for injectable peptides across indications such as migraines, ulcerative colitis, and osteoporosis. This follows a June 2026 review by FDA scientists, who recommended against changing the status of any of the peptides.

Many members of the committee have reported ties to the peptide industry, including work for clinics offering injectable peptides or compounding pharmacies. Aaron Kesselheim, a professor at Harvard Medical School and Brigham and Women's Hospital, stated, "I think what's going on here is the advisory committee may be stacked with people who are known to have certain viewpoints on a topic rather than who are coming at this in an unconflicted and unbiased way." A Department of Health and Human Services spokesperson said all committee members underwent an ethics and vetting process and noted the agency's commitment to robust discussions.

Lee Rosebush, a pharmacist and attorney who represents peptide makers, said, "The FDA's actions during the Biden administration opened up the Wild Wild West." He added, "Nobody is recommending these peptides. This is about ensuring patients have safe and effective access to these medications." Rosebush noted, "These products will likely never go through an FDA approval process. So without allowing compounding pharmacies to do this, patients will never get access." The therapies have not undergone large-scale trials typically required for FDA approval.

Rita Jew, president of the Institute for Safe Medication Practices, expressed concerns. Jew stated, "With anything that you're taking, whether it's an FDA-approved product or a supplement, you always have to weigh the risk versus benefit." She added, "These peptides really do not have established effectiveness, so the only thing you have is risk." Kesselheim said, "That's why this discussion is so important and why the FDA's authority here is an important one to exercise appropriately with optimal outside advice."

Peptides are strings of amino acids smaller than proteins that function as signaling molecules in the body. Insulin is a naturally occurring peptide used as a drug, and GLP-1 weight loss drugs are modified peptides that underwent extensive human trials. FDA leadership retains final authority on whether these peptides can be compounded.